Plain-English translation of NCT06584227 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of four medications—adebrelimab, chidamide, gemcitabine, and S1—as a first-line treatment for pancreatic cancer that has spread or cannot be removed with surgery. The study is designed to see whether this new combination works better than existing treatments, and to understand how safe it is for patients.
Pancreatic cancer is difficult to treat, and current first-line medications only help patients survive for about 6 to 11 months on average. Doctors and researchers are looking for better options, especially ones that might harness the immune system to fight the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
You would receive the four-drug combination as part of your cancer treatment plan. This likely involves regular visits to the hospital or clinic for infusions and oral medications, along with blood tests and scans to monitor how well the treatment is working and check for side effects. The study will follow your health and survival over time to see whether this new combination is effective and safe.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China